Marico Q1 FY26 revenue rose 23% to Rs 3,259 crore; profit up 8% (resurfacing August 2025 results)

Resurfacing a report from early August 2025: Marico’s India revenue grew 27% year on year to Rs 2,495 crore in Q1 FY26, while international revenue rose 13%. The FMCG company also increased its fully diluted stake in Plix maker Satiya Nutraceuticals to 60% amid an outlook for continued volume and revenue momentum.

— FiledThu, 10 Sept, 2026, 06:35 IST·First seen Thu, 10 Sept, 2026, 06:34 IST·Source Financial Express · BrandWagon

What happened

Marico reported strong Q1 FY26 performance, with India revenue up 27.2% and consolidated revenue up 23.3%. The FMCG company increased its stake in Plix maker

Key facts

  • Q1 FY26 consolidated net profit Rs 513 crore, up 8.2% YoY from Rs 474 crore
  • Revenue from operations Rs 3,259 crore, up 23.31% YoY from Rs 2,643 crore
  • Total income Rs 3,315 crore, including Rs 56 crore other income
  • Total expenses Rs 2,659 crore versus Rs 2,075 crore
  • India revenue Rs 2,495 crore, up 27.17% YoY from Rs 1,962 crore
  • International revenue Rs 764 crore, up 12.91% YoY from Rs 681 crore
  • India profit before tax Rs 469 crore
  • International profit before tax Rs 213 crore
  • Marico raised its Satiya Nutraceuticals stake to 60% fully diluted

Why this matters

By raising its stake in Plix maker Satiya Nutraceuticals to 60%, Marico is deepening its position in the high-growth nutrition and wellness category.

What to watch

  • Sequential India volume growth versus price-led revenue growth.
  • Gross-margin trend and management commentary on copra, vegetable oil and packaging inflation.
  • Advertising-and-promotion spend as a percentage of sales.
  • Plix revenue growth, profitability, channel expansion and integration milestones.
  • Rural demand recovery and the pace of growth in value-pack sales.
  • International business growth and currency effects.
  • Further portfolio investments or acquisitions in wellness, nutrition and digital-first brands.
  • Prioritize advertising, distribution and innovation behind India franchises while maintaining selective pricing.
  • Integrate Plix more deeply across sales, supply chain, e-commerce and brand-building capabilities.
  • Use premiumization in foods, personal care and wellness to offset pressure on core-category gross margins.
  • Expand international-market execution selectively, with focus on markets delivering profitable double-digit growth.
  • Monitor working capital and acquisition-related costs as the higher stake in Satiya Nutraceuticals is consolidated.